Clover Health awards accounting chief 186,403 shares

The award vests in stages through November 4, 2030, with each vesting date conditional on continued service.

Available on EDGAR 11/06/2026 - 06:45 PM EST Accepted by SEC EDGAR 11/06/2026 - 06:44 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) Chief Accounting Officer Joseph Frank Oldakowski received an award covering 186,403 shares of Class A common stock on November 4, 2026. Twenty-five percent of the restricted stock units will vest on the first anniversary of that date, with the remaining units vesting in 12 equal quarterly installments beginning three months later. Vesting is subject to continued service on each vesting date, and the award will be fully vested on November 4, 2030. His direct position following the transaction was 462,300 shares.

Insider Trade Summary

Grant/Award: 186,403 shares

Grant/Award 1 txn

Insider OLDAKOWSKI JOSEPH FRANK

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock F1	186,403	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 462,300 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Class A common stock underlying a time-based restricted stock unit award ("RSUs"). Twenty-five percent of the RSUs will vest on the first anniversary of November 4, 2026, and the remaining RSUs will vest in twelve equal quarterly installments beginning on the date that is three months after the first anniversary of November 4, 2026, in each case subject to the continued service of the Reporting Person on each such vesting date, so that such RSUs will be fully vested on November 4, 2030.

Key Figures

Award shares: 186,403 shares Direct position following transaction: 462,300 shares Initial vesting portion: 25% +2 more

5 metrics

Award shares 186,403 shares Time-based restricted stock unit award on November 4, 2026

Direct position following transaction 462,300 shares After the November 4, 2026 transaction

Initial vesting portion 25% Vests on the first anniversary of November 4, 2026, subject to continued service

Remaining vesting installments 12 equal quarterly installments Beginning three months after the first anniversary of November 4, 2026

Full vesting date November 4, 2030 Subject to continued service on each vesting date

Key Terms

time-based restricted stock unit award, quarterly installments, continued service

3 terms

time-based restricted stock unit award financial

"time-based restricted stock unit award ("RSUs")"

quarterly installments financial

"in twelve equal quarterly installments"

continued service financial

"subject to the continued service of the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CLOV shares were covered by the chief accounting officer's award?

Joseph Frank Oldakowski, Clover Health Investments' Chief Accounting Officer, received an award covering 186,403 shares of Class A common stock on November 4, 2026.

When do the CLOV restricted stock units vest?

Twenty-five percent of the RSUs will vest on the first anniversary of November 4, 2026, and the remaining RSUs in 12 equal quarterly installments beginning three months after that anniversary. Vesting is subject to continued service on each vesting date, and the award will be fully vested on November 4, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLDAKOWSKI JOSEPH FRANK

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/04/2026		A		186,403(1)	A	$0	462,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A common stock underlying a time-based restricted stock unit award ("RSUs"). Twenty-five percent of the RSUs will vest on the first anniversary of November 4, 2026, and the remaining RSUs will vest in twelve equal quarterly installments beginning on the date that is three months after the first anniversary of November 4, 2026, in each case subject to the continued service of the Reporting Person on each such vesting date, so that such RSUs will be fully vested on November 4, 2030.

Remarks:

	/s/ Peter J. Rivas as attorney-in-fact for Joseph Frank Oldakowski	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)